ID   A375 PLX/AZD-resistant
AC   CVCL_C0Q6
DR   cancercelllines; CVCL_C0Q6
DR   PRIDE; PXD026952
DR   Wikidata; Q112927056
RX   PubMed=35128241;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_63637; Vemurafenib (Zelboraf; PLX4032).
CC   Selected for resistance to: ChEBI; CHEBI_90227; Selumetinib (AZD6244).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Omics: Proteomics; Quantitative.
CC   Derived from site: In situ; Leg, skin; UBERON=UBERON_0001511.
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0132 ! A-375
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 10-04-25; Version: 8
//
RX   PubMed=35128241; DOI=10.1021/acsomega.1c05361; PMCID=PMC8811929;
RA   Martinez R. 3rd, Huang W.-L., Buck H., Rea S., Defnet A.E., Kane M.A.,
RA   Shapiro P.;
RT   "Proteomic changes in the monolayer and spheroid melanoma cell models
RT   of acquired resistance to BRAF and MEK1/2 inhibitors.";
RL   ACS Omega 7:3293-3311(2022).
//